KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Non-Current Deferred Tax Liability (2016 - 2025)

Historic Non-Current Deferred Tax Liability for West Pharmaceutical Services (WST) over the last 17 years, with Q3 2025 value amounting to $22.8 million.

  • West Pharmaceutical Services' Non-Current Deferred Tax Liability rose 14255.32% to $22.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.8 million, marking a year-over-year increase of 14255.32%. This contributed to the annual value of $20.5 million for FY2024, which is 7593.9% down from last year.
  • Per West Pharmaceutical Services' latest filing, its Non-Current Deferred Tax Liability stood at $22.8 million for Q3 2025, which was up 14255.32% from $23.0 million recorded in Q2 2025.
  • Over the past 5 years, West Pharmaceutical Services' Non-Current Deferred Tax Liability peaked at $85.2 million during Q4 2023, and registered a low of $1.2 million during Q2 2022.
  • Over the past 5 years, West Pharmaceutical Services' median Non-Current Deferred Tax Liability value was $15.4 million (recorded in 2023), while the average stood at $23.2 million.
  • Per our database at Business Quant, West Pharmaceutical Services' Non-Current Deferred Tax Liability tumbled by 9016.39% in 2022 and then surged by 118333.33% in 2023.
  • Over the past 5 years, West Pharmaceutical Services' Non-Current Deferred Tax Liability (Quarter) stood at $48.6 million in 2021, then skyrocketed by 63.37% to $79.4 million in 2022, then increased by 7.3% to $85.2 million in 2023, then crashed by 75.94% to $20.5 million in 2024, then grew by 11.22% to $22.8 million in 2025.
  • Its last three reported values are $22.8 million in Q3 2025, $23.0 million for Q2 2025, and $21.3 million during Q1 2025.